Ph.D., CEO, Travera
Biography
Clifford Reid is the founding CEO of Travera. Previously, Dr. Reid was the founding Chairman, President and Chief Executive Officer of Complete Genomics (NASDAQ:GNOM), a leading developer of whole human genome DNA sequencing technologies and services. Prior to Complete Genomics he founded two enterprise software companies: Eloquent (NASDAQ:ELOQ), an internet video company, and Verity (NASDAQ:VRTY), an enterprise search engine company. Dr. Reid is on the Visiting Committee of the Biological Engineering Department at the Massachusetts Institute of Technology (MIT), a member of the MIT Corporation Development Committee, and an advisor to Warburg Pincus. He earned a S.B. in Physics from MIT, an MBA from the Harvard Business School, and a Ph.D. in Management Science and Engineering from Stanford University.
Clinical Dx Showcase:
Travera
Travera has developed a new technology for identifying effective cancer drugs and drug combinations for cancer patients. We use a new measurement device invented at MIT to weigh single cells with sub-picogram accuracy, directly measuring the ex vivo response of cancer cells to cancer drugs.
A Universal Cancer Biomarker for Rapid Therapy Guidance
Travera has developed a new technology for identifying effective cancer drugs for cancer patients. We use a new measurement device invented at MIT to weigh single cells with sub-picogram accuracy, directly measuring the ex vivo response of cancer cells to cancer drugs.
Session Abstract – PMWC 2022 Silicon Valley
Track 6 - June 28 9.00 A.M.-4.45 P.M.,Track 6 - June 29 3.30 P.M.-3.45 P.M.,Track 6 - June 30 9.00 A.M.-1.15 P.M.
The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative
